A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Launched by PFIZER · Nov 30, 2023
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called ritlecitinib to see how safe and effective it is for people with non-segmental vitiligo, a skin condition that causes white patches due to a loss of pigment. The trial will explore if continuing ritlecitinib helps patients keep or improve their skin color recovery, or if starting a higher dose of ritlecitinib can lead to better results. Participants will take either ritlecitinib or a placebo (a pill with no active medication) for up to 52 weeks and will have regular check-ins to monitor their progress.
To join this study, participants need to be at least 12 years old, have non-segmental vitiligo, and have completed a previous study involving ritlecitinib or a placebo. During the trial, they will take the medication daily at home and attend up to nine visits to the study site for evaluations. This study aims to understand how ritlecitinib can help manage vitiligo better, contributing to potential improvements in treatment for this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants ≥18 years of age at Screening in Study B7981040. Adolescents (12 to \<18 years of age at Screening in the parent study) are also eligible for this study if approved by the local IRB/EC and regulatory health authority.
- • Participants who met the eligibility criteria and completed 52 weeks of study intervention for stable or active nonsegmental vitiligo in Study B7981040
- • The BL visit/first dose in Study B7981041 must be within 30 days after the week 52 visit in Study B7981040
- Exclusion Criteria:
- • Participant met the parent study (Study 7981040) discontinuation criteria or discontinued the parent study for any safety-related event
- • Any active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Charleston, South Carolina, United States
Melbourne, Victoria, Australia
San Antonio, Texas, United States
Barcelona, , Spain
Sendai, Miyagi, Japan
Cordoba, , Spain
Shinjuku Ku, Tokyo, Japan
Indianapolis, Indiana, United States
Seoul, , Korea, Republic Of
Bunkyo Ku, Tokyo, Japan
Nagoya, Aichi, Japan
Quebec, , Canada
Cleveland, Ohio, United States
Shanghai, Shanghai, China
Bad Bentheim, Niedersachsen, Germany
Chapel Hill, North Carolina, United States
Madrid, , Spain
Seoul, , Korea, Republic Of
Dallas, Texas, United States
Fuzhou, Fujian, China
Brooklyn, New York, United States
Fuzhou, Fujian, China
Suwon, , Korea, Republic Of
Kofu, Yamanashi, Japan
Quebec, , Canada
Sendai Shi, Miyagi, Japan
Guangzhou, Guangdong, China
Kunming, Yunnan, China
Tokyo, , Japan
Encinitas, California, United States
London, , United Kingdom
Las Palmas De Gran Canaria, Las Palmas, Spain
Columbus, Ohio, United States
Münster, Nordrhein Westfalen, Germany
Monterrey, Nuevo León, Mexico
Tampa, Florida, United States
Huntington Beach, California, United States
Seoul, Other, Korea, Republic Of
Ostrowiec Swietokrzyski, , Poland
Suwon Si, , Korea, Republic Of
Veracruz, , Mexico
Los Angeles, California, United States
Wilmington, North Carolina, United States
Campbelltown, South Australia, Australia
Carlton, Victoria, Australia
Mississauga, Ontario, Canada
Sakai, Osaka, Japan
Rockville, Maryland, United States
Baton Rouge, Louisiana, United States
Osielsko, Kujawsko Pomorskie, Poland
Darlinghurst, New South Wales, Australia
Markham, Ontario, Canada
Seoul, Seoul Teukbyeolsi [Seoul], Korea, Republic Of
Cordoba, Andalucía, Spain
Red Deer, Alberta, Canada
Sakai City, Osaka, Japan
Houston, Texas, United States
Guangzhou, Guangdong, China
Calgary, Alberta, Canada
Columbus, Ohio, United States
Hollywood, Florida, United States
Warszawa, Mazowieckie, Poland
Sofia, , Bulgaria
Boynton Beach, Florida, United States
Barcelona, Catalunya [Cataluña], Spain
Albuquerque, New Mexico, United States
Mexico City, Distrito Federal, Mexico
Istanbul, , Turkey
Stara Zagora, , Bulgaria
Largo, Maryland, United States
Dupnitsa, Kyustendil, Bulgaria
Sofia, Sofia (Stolitsa), Bulgaria
Houston, Texas, United States
Toronto, Ontario, Canada
Suwon, Kyǒnggi Do, Korea, Republic Of
Suwon Si, Kyǒnggi Do, Korea, Republic Of
Chapel Hill, North Carolina, United States
Lodz, łódzkie, Poland
Szczecin, Zachodniopomorskie, Poland
Wuhan, Hubei, China
Stuttgart, Baden Württemberg, Germany
Shenyang, Liaoning, China
Monterrey, , Mexico
Wilmington, North Carolina, United States
Kayseri, , Turkey
East Melbourne, Victoria, Australia
Córdoba, , Spain
Sakai City, Osaka, Japan
Ostrowiec Swietokrzyski, świętokrzyskie, Poland
Veracruz, , Mexico
Guangzhou, Guangdong, China
Manisa, , Turkey
Quebec, , Canada
Stuttgart, , Germany
Lodz, , Poland
Istanbul Fatih, Istanbul, Turkey
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported